- Home
- AMRN vs XFOR Comparison
AMRN vs XFOR Comparison
Compare AMRN & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMRN | XFOR |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.9M | 288.5M |
| IPO Year | 1998 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AMRN | XFOR |
|---|---|---|
| Price | $11.67 | $3.03 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $12.50 | $11.60 |
| AVG Volume (30 Days) | 60.2K | ★ 849.7K |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,104,000.00 | $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 39.22 | ★ 150.00 |
| 52 Week Low | $11.25 | $2.43 |
| 52 Week High | $20.90 | $4.83 |
Technical Indicators
Market Signals| Indicator | AMRN | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 25.75 | 42.55 |
| Support Level | N/A | N/A |
| Resistance Level | $15.34 | $2.97 |
| Average True Range (ATR) | 0.35 | 0.16 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 13.13 | 71.03 |
Price Performance
Historical ComparisonAbout AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.